Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.69 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120538 | 0.94 | ELANE (0.78) | ELANECYP2C9CYP2C19 | |
| SCHEMBL125599 | 0.93 | ELANE (0.76) | ELANECYP2C9CYP2C19 | |
| SCHEMBL172156 | 0.90 | ELANE (0.80) | ELANECYP2C9CYP2C19 | |
| SCHEMBL123893 | 0.90 | ELANE (0.80) | ELANECYP2C9CYP2C19 | |
| SCHEMBL123843 | 0.90 | ELANE (1.00) | ELANECYP2C9CYP2C8CYP2C19ADRB1 | |
| SCHEMBL125346 | 0.90 | ELANE (1.00) | ELANECYP2C9CYP2C8CYP2C19ADRB1 | |
| SCHEMBL120539 | 0.88 | ELANE (0.73) | ELANECYP2C9CYP2C19 | |
| SCHEMBL172164 | 0.87 | ELANE (0.69) | ELANECYP2C9CYP2C19 | |
| SCHEMBL12859294 | 0.87 | ELANE (1.00) | ELANECYP2C9CYP2C19 | |
| SCHEMBL12859296 | 0.87 | ELANE (1.00) | ELANECYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | TNNI3, TNNT2, PC | ELANE 1598/4885CYP2C9 582/4885CYP2C8 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.